PDF(Pubmed)
Abstract：
COVID-19 is an airborne respiratory disease that mainly affects the lungs. To date, COVID-19 has infected 580 million people with a mortality of approximately 7 million people worldwide. The emergence of COVID-19 has also affected the infectivity, diagnosis, and disease outcomes of existing diseases such as influenza, TB, and asthma in human populations. These are airborne respiratory diseases with symptoms and mode of transmission similar to those of COVID-19. It was speculated that the protracted nature of the COVID-19 pandemic coupled with vaccination could impact other respiratory diseases and mortality. In this study, we analyzed the impact of COVID-19 on flu, tuberculosis (TB), and asthma. Our analyses suggest that COVID-19 has a potential impact on the mortality of flu, TB, and asthma. These impacts vary across before the COVID-19 era, during the peak period of the pandemic, and after vaccinations/preventive measures were implemented, as well as across different regions of the world. Overall, the spread of flu generally reduced during the pandemic, resulting in a reduced expenditure on flu-related hospitalizations, although there were sporadic spikes at setting times. In contrast, TB deaths generally increased perhaps due to the disruption in access to TB services and reduction in resources. Asthma deaths, on the other hand, only marginally varied. Collectively, the emergence of COVID-19 added extra cost to the overall expenditure on some respiratory infectious diseases, while the cost for other infectious diseases was either reduced or somewhat unaffected.
摘要：
COVID-19是一种空气传播的呼吸道疾病，主要影响肺部。迄今为止,新冠肺炎感染了5.8亿人，全球约700万人死亡。COVID-19的出现也影响了传染性，诊断,和现有疾病如流感的疾病结果，TB,人群中的哮喘。这些是空气传播的呼吸道疾病，其症状和传播方式与COVID-19相似。据推测，COVID-19大流行的长期性加上疫苗接种可能会影响其他呼吸道疾病和死亡率。在这项研究中,我们分析了COVID-19对流感的影响，结核病（TB），和哮喘。我们的分析表明，COVID-19对流感的死亡率有潜在影响，TB,和哮喘。这些影响在COVID-19时代之前各不相同，在大流行的高峰期，在实施疫苗接种/预防措施后，以及世界各地的不同地区。总的来说,流感在大流行期间的传播普遍减少，导致流感相关住院治疗的支出减少，尽管在设定时间有零星的尖峰。相比之下,结核病死亡人数普遍增加，可能是由于获得结核病服务的中断和资源减少。哮喘死亡,另一方面,只是略有变化。总的来说，COVID-19的出现增加了一些呼吸道传染病的总支出，而其他传染病的费用要么降低，要么不受影响。
